18 Aug
Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction
Posted in Sexual Dysfunction on 18.08.10 by Merlyn |
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained …
Comments Off